Bone Biologics is a publicly traded company based in Boston, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1 provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.
Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.
Scientific Advisory Board
Dr. Shunichi Kuroda, PhD
Executive Officer, Beacle, Inc.
Dr. Shunichi Kuroda, Ph.D. co-founded Bone Biologics, Inc. Dr. Kuroda is an Associate Professor in the Department of Structural Molecular Biology, the Director of the Institute of Scientific and Industrial Research (ISIR),Osaka University, Ibaraki, Japan. He has been an Executive Officer of Beacle, Inc. since 2004. Dr. Kuroda served as Guest Professor at University of Geneva since 2002 and Associate Professor at Kobe University Bio-signal Research Center since 1994. He served at Takeda Pharmaceutical Co., Ltd. since 1986 and has been a Member of Scientific Advisory Board at Bone Biologics, Inc. since 2005. Dr. Kuroda graduated with a Ph.D. from Kyoto University in 1986.
Dr. Jeffrey C. Wang, MD
Chief of Orthopaedic Spine Service, Co-Director USC Spine Center, and Professor of Orthopaedic Surgery and Neurosurgery at USC Spine Center
Dr. Wang was recruited in 2013 to lead the building of the University of Southern California Spine Center. He is currently a Professor of Orthopaedic Surgery and Neurosurgery at the Keck Medical Center at USC. He is Co-Director of the USC Spine Center and Fellowship Director of the USC Spine Fellowship. His research areas include the use of osteoinductive and osteoconductive materials for spinal fusion as well as novel gene therapy and minimally invasive techniques for spinal surgery. He obtained his undergraduate degree from Stanford University and his medical degree from the University of Pittsburgh. In 1997, he joined the David Geffen School of Medicine at UCLA as Assistant Professor of Orthopaedic Surgery. In 2002 he was appointed Assistant Professor of Neurosurgery and became Associate Professor in both disciplines in 2003, when he was designated Executive Director of the UCLA Comprehensive Spine Center.
While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.
Bone Biologics was founded in 2004 by Dr. Chia Soo, MD/Vice-Chair and Professor, UCLA Hospital Dept of Orthopedic Surgery; Dr. Kang Ting DMD, DMSc/Professor, UCLA Dental School; and Dr. Benjamin Wu, DDS, PhD/Chair and Professor, UCLA Dept of Bioengineering.The Company was acquired in 2006 by MTF, the major shareholder and primary funder since the acquisition.
Headquartered in Boston, Massachusetts, USA, Bone Biologics became a public company in September 2014 and is focused on bone repair and regeneration applications. The company is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.
For information regarding our company and/or products, please complete the form below.